SEC Filing Analysis: PHIBRO ANIMAL HEALTH CORP (PAHC)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The President and CEO, Jack Bendheim, sold 7,040 shares for approximately $297k under a pre-arranged Rule 10b5-1 trading plan.
• Market Impact: Minimal, as the transaction is small in scale and was pre-scheduled, indicating it is not based on recent material non-public information.

Company Information

Field	Value
Company	PHIBRO ANIMAL HEALTH CORP
Ticker Symbol	PAHC
CIK	0001069899
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	BENDHEIM JACK
CIK	0001241560
Title/Position	President and CEO
Relationship	Director, Officer, 10% Owner

Transaction Details

This analysis aggregates multiple sale transactions reported in the filing.

Field	Value
Form Type	4
Transaction Date	2025-11-04 & 2025-11-05
Transaction Code	S (Sale)
Security Type	Class A Common Stock
Shares Involved	7,040
Average Price Per Share	$42.16
Total Value	$296,778.35
Shares Owned After	79,240 (16,840 Direct, 62,400 Indirect)
Ownership Type	Indirect (sales) & Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$296,778.35
% of Market Cap	0.018%
Shares Transacted	7,040
% of Shares Outstanding	0.035%
Post-Transaction Ownership	79,240 shares (0.39% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value of ~$297k is negligible against Phibro's market capitalization of $1.67 billion.
• Ownership Concentration: The sale has a minimal impact on the insider's overall ownership stake, which remains at approximately 0.39% of outstanding shares (excluding Class B holdings).
• Transaction Significance: The sale is not significant from a financial perspective, representing a tiny fraction of both market cap and shares outstanding. The pre-planned nature further diminishes its importance as a market signal.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is minor and was executed under a Rule 10b5-1 plan, which allows insiders to set up a trading plan for selling stocks at a predetermined time. This removes the element of insider discretion based on current events.

Volume & Sentiment

• Expected Volume Impact: Negligible. The number of shares sold is too small to materially affect trading volume.
• Sentiment Indicator: Neutral. The market generally views sales under 10b5-1 plans as non-events unless the volume is exceptionally large.

Additional Context

Transaction Notes

• Special Circumstances: The filing explicitly states the sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025. The filing also details a conversion of 25,000 Class B shares into Class A shares, which preceded the sales.